RT Journal Article
SR Electronic
T1 Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.04.20187088
DO 10.1101/2020.09.04.20187088
A1 Wang, Limin
A1 Candia, Julián
A1 Ma, Lichun
A1 Zhao, Yongmei
A1 Imberti, Luisa
A1 Sottini, Alessandra
A1 Dobbs, Kerry
A1 ,
A1 Lisco, Andrea
A1 Sereti, Irini
A1 Su, Helen C.
A1 Notarangelo, Luigi D.
A1 Wang, Xin Wei
YR 2020
UL http://medrxiv.org/content/early/2020/09/07/2020.09.04.20187088.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic respiratory infectious disease COVID-19. However, clinical manifestations and outcomes differ significantly among COVID-19 patients, ranging from asymptomatic to extremely severe, and it remains unclear what drives these disparities. Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses. SARS-CoV-2 infection was associated with a marked increase in individual’s immune memory antibody repertoires linked to trajectories of disease severity from the longitudinal analysis also including anti-spike protein antibodies. By applying a machine-learning-based strategy, we developed a viral exposure signature predictive of COVID-19-related disease severity linked to patient survival. These results provide a basis for understanding the roles of memory B-cell repertoires in COVID-19-related symptoms as well as a predictive tool for monitoring its clinical severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by grants from the Intramural Research Program of the Center for Cancer Research of the National Cancer Institute (grant ZIA BC 011951 to XWW), the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (grant AI001270-01 to LDN) and by Regione Lombardia, Italy (project Risposta immune in pazienti con COVID-19 e comorbidita to LI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Deidentified discarded blood samples and clinical information were obtained under protocol NP-4000 approved by Comitato Etico Provinciale, Brescia, Italy. Because deidentified samples were provided, no informed consent was used. The NIH IRB from OHSR office considered this study non human subject research and determined that this study is exempted from ethics oversight.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request